A phase 1, open label, parallel design, single dose, three-cohort study of drug-drug interaction study between Islatravir and Lenacapavir in healthy volunteers
Latest Information Update: 31 Mar 2022
At a glance
- Drugs Islatravir (Primary) ; Lenacapavir (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 31 Mar 2022 New trial record
- 16 Feb 2022 Preliminary results (n=56) presented at the 29th Conference on Retroviruses and Opportunistic Infections.